Clinical Development Failure: The success of SNSE hinges entirely on the outcome of its clinical trials, which are inherently uncertain and prone to delays, unexpected side effects, or a lack of efficacy, potentially leading to the discontinuation of its lead candidates.

Regulatory Approval Uncertainty: Even with positive clinical data, there is no guarantee that regulatory authorities like the FDA will approve SNSE's product candidates, a process that is lengthy, expensive, and subject to their discretion and evolving standards.

Significant Capital Requirements: SNSE is a clinical-stage company with no revenue, relying heavily on external financing to fund its research, development, and operational activities, raising substantial doubt about its ability to secure sufficient future funding without significant stock dilution.